Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing

Executive Summary

Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.

You may also be interested in...



Keeping Track: Submissions Galore, Blincyto Supplemental Approval, And Priority Review For Opdivo/Yervoy Combo

The latest drug development news and highlights from our US FDA Performance Tracker.

Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash

Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.

No Break For Sanofi: Seals Another Diabetes Deal

Having just secured a deal with Hanmi Pharmaceutical for its long-acting diabetes products, Sanofi has wasted no time in boosting its diabetes franchise again, by entering into an agreement with Lexicon Pharmaceuticals for sotagliflozin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel